Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220013/S034

TactiFlex Ablation Catheter, Sensor Enabled

ABBOTT MEDICAL · Decision date Sep 22, 2026

MEDTECHLEDGER EXPLANATIONP220013/S034

What did the FDA approve?

FDA records an approval decision dated 2026-09-22 for P220013/S034, a 30-day notice supplement (review track 135) filed by Abbott Medical under product code OAE for the TactiFlex Ablation Catheter, Sensor Enabled, a percutaneous cardiac ablation catheter for atrial fibrillation. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier.

The stated scope is approval of a predetermined change control plan, TactiFlex Ablation Catheter, Sensor Enabled Predetermined Change Control Plan Version A, covering a change to the manufacturing location of the deflectable subassembly for the device. This supplement concerns that manufacturing plan and does not represent approval of a new device or system; the source does not describe clinical data, performance testing, or the specific new location, so no conclusion about safety or effectiveness follows from the decision record.

FDA approval order statement

approval for a predetermined change control plan (PCCP) TactiFlex Ablation Catheter, Sensor Enabled Predetermined Change Control Plan Version A that encompasses the change to the manufacturing location of the deflectable subassembly for subject catheter.
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 22, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P220013/S034
Regulatory pathway
PMA supplement
Product code
OAE
Decision code
APPR
Decision date
Sep 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.

Product code
OAE
FDA device class
3

For the original device and its historical approval scope, see PMA P220013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220013 · Original PMA

    TactiFlex Ablation Catheter, Sensor Enabled, TactiSys Quartz Equipment, TactiSys Quartz, TactiFlex Radiofrequency C

  2. P220013/S034 received

    Application receipt date recorded by FDA.

  3. P220013/S028 · Related supplement

    TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDM

  4. P220013/S034 · FDA decision

    135 Review Track For 30-Day Notice

Timeline entries are records held by MedtechLedger for P220013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220013

Explore the linked device profile

Other records with product code OAE

Product / regulatory recordCompanyPathwayDecision dateSource
STOP Persistent AFP100010/S154
Medtronic Cryocath, LPPMA supplementSep 25, 2026FDA
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
QDOT MICRO SystemP210027/S018
Biosense Webster, Inc.PMA supplementSep 10, 2026FDA
Biosense Webster, Inc.PMA approvalNov 23, 2022FDA
Medtronic Cryocath, LPPMA approvalDec 17, 2010FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
5050 Nathan Ln. N., Plymouth, MN, 55442

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records